Key points are not available for this paper at this time.
To the editor: The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib sets a new standard of care for the treatment of patients with relapsed or refractory chronic lymphocytic leukemia (CLL)11,22 and mantle cell lymphoma (MCL).33 Ibrutinib is generally well tolerated and largely
McMullen et al. (Thu,) studied this question.